Site-Specific Chemical Linker for Antibody-Drug Conjugates
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antibody-drug conjugates face challenges with linker stability in plasma, leading to decreased drug efficacy and increased toxic side effects due to instability and non-specific conjugation methods.
Innovation Solution
A novel linker structure is developed for site-specific conjugation, providing high reactivity, mild conditions, and uniform bioactive conjugate formation with enhanced plasma stability and efficacy, using specific chemical structures and conjugation methods.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If non-site-specific conjugation is used, then the conjugation process is simple, but the uniformity of the antibody-drug conjugate is poor
Solution Approach 1:
The patent introduces a site-specific conjugation method where a linker is pre-installed at a specific location on the antibody (such as the N-terminus of the heavy chain) before drug conjugation. This preliminary action ensures that subsequent drug attachment occurs at a defined site, improving conjugate uniformity while maintaining reasonable process simplicity.
Solution Approach 2:
The patent uses a specially designed linker as an intermediary component between the antibody and the cytotoxic drug. This linker contains specific functional groups that enable site-specific attachment to the antibody and controlled drug conjugation, thereby achieving uniform conjugates through a structured intermediate step rather than direct random conjugation.
2Manufacturing precision
If site-specific conjugation through genetic engineering or enzymatic methods is used, then the conjugate uniformity is improved, but the structural stability of the antibody may be impacted and CMC requirements increase
Solution Approach 1:
The patent employs chemical conjugation methods that modify specific parameters of the antibody (such as utilizing the N-terminus amino group) without requiring genetic engineering or enzymatic modification. This approach achieves site-specific conjugation while preserving the overall structural stability of the antibody and avoiding complex CMC requirements associated with biological modification methods.
3Productivity
If DBM linkers are used for chemical conjugation, then the conjugation efficiency is improved, but the linker stability in plasma decreases leading to decreased drug efficacy and increased toxic side effects
Solution Approach 1:
The patent designs linkers with differentiated local properties: one end of the linker is highly reactive for efficient conjugation to the antibody N-terminus, while the other end maintains stability in plasma conditions. This local quality differentiation allows the linker to perform both conjugation and stable drug delivery functions, resolving the contradiction between conjugation efficiency and plasma stability.
Solution Approach 2:
The patent employs composite linker structures that combine different chemical moieties with complementary properties. The linker may include stable backbone structures (such as PEG chains or rigid aromatic systems) combined with reactive functional groups, creating a composite material that achieves both high conjugation efficiency and sustained plasma stability, thereby maintaining drug efficacy and reducing toxic side effects.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The novel linker enables stable and uniform conjugation, maintaining drug efficacy and reducing side effects by ensuring consistent delivery of the cytotoxic payload to tumor sites.
Implementation Method 1
A conjugation mode refers to the connection mode between the antibody and the drug-linker
Implementation Method 2
the obtained bioactive conjugate has good uniformity and plasma stability
Data Source
AI summary
The present invention relates to a chemical coupling linker and use thereof, and a bioactive conjugate prepared by the chemical coupling linker. The present invention also relates to use of the bioactive conjugate in the preparation of a drug for the prevention or treatment of tumor diseases.